Compare RRBI & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRBI | CMPS |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.7M | 778.7M |
| IPO Year | 2019 | 2020 |
| Metric | RRBI | CMPS |
|---|---|---|
| Price | $88.12 | $6.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $67.00 | $27.14 |
| AVG Volume (30 Days) | 37.8K | ★ 4.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 28.89 | 0.86 |
| EPS | ★ 6.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $30.10 | N/A |
| P/E Ratio | $13.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.33 | $2.25 |
| 52 Week High | $93.90 | $8.90 |
| Indicator | RRBI | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 54.22 | 40.28 |
| Support Level | $85.35 | $5.95 |
| Resistance Level | $92.74 | $7.02 |
| Average True Range (ATR) | 2.72 | 0.46 |
| MACD | -0.48 | -0.12 |
| Stochastic Oscillator | 58.18 | 3.82 |
Red River Bancshares Inc is the bank holding company for the red river bank. The principal business of the Bank is lending and accepting deposits from businesses, professionals, individuals, and public entities. The bank's primary deposit products are demand deposits, savings deposits, and time deposits. The bank maintains a diversified loan portfolio with a focus on commercial real estate (Owner Occupied and Non-Owner Occupied), one-to-four-family residential, commercial, and industrial loans, construction and development Loans, and others. also, provides Treasury Management Services, Private Banking Services, Brokerage Services, and Other Banking Services.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.